Brookline Capital Management issued their Q3 2025 earnings estimates for shares of CRISPR Therapeutics in a report released ...

Sequencing bacterial genomes allows scientists to study bacterial diversity, immunity, and the human microbiome, but it ...

We recently published a list of Shares of 10 Firms Soar on Friday. In this article, we are going to take a look at where ...

A team of researchers from the Hefei Institutes of Physical Science of the Chinese Academy of Sciences has developed a ...

Researchers have revealed new details about the CRISPR-Cas5-HNH/Cascade complex, a variant of the type I-E CRISPR-Cas system, ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...

Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note ...

A CRISPR-based system that erases itself from fly populations may offer a safer approach to tackling insecticide resistance ...